Objective To explore the clinical effificacy of Isomaltoside Iron in patients with maintenance hemodialysis(MHD)combined with iron defificiency anaemia(IDA).Methods 61 patients with MDH combined with IDA in our hospital's blood pu-rification center from June 2021 to June 2022 were selected and divided into sucrose iron group(29 cases)and isomaltoside iron group(32 cases)according to different treatment drugs.Patients in the sucrose iron group were treated with Sucrose Iron,while those in the isomaltoside iron group were treated with Isomaltoside Iron.After 3 months of continuous treatment,the changes in biochemical indicators(urea nitrogen,creatinine,PTH,hemoglobin,ferritin,transferrin saturation)and adverse reaction were compared between the two groups.Results Before treatment,there was no statistically significant difference between the clinical indicators of the two groups.After 3 months of treatment,there was no statistically significant difference in serum BUN,Scr,UA and PTH between the two groups.both the two groups had an increase in hemoglobin、ferritin and transferrin saturation levels,and the isomaltoside iron Group increased more significantly than sucrose iron group,which was statistically significant.At the same time,There is no statistically significant difference in the incidence of adverse events between the two groups of patients.Conclusion Compared with sucrose iron,isomaltoside iron induced a non-inferior haematological response,comparably low rates of hypersensitivity reactions,and exhibits faster effects,without increasing the incidence of adverse reactions.
NETL
NSTL
万方数据
